PIK3CA Q75E

CI-VAR-00003589Explore in graph →CIViC 5043

Curated evidence

Evidence by cancer (2 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–2 of 2 evidence items across 1 cancer context on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Squamous Cell Carcinoma2
PIK3CA N345K OR PIK3CA M1043V OR PIK3CA Q75E	Alpelisib	Predictive	D	Supports Sensitivity Response	2	submitted	EID12160 In this pre-clinical study, the role of the non-canonical PIK3CA mutation PIK3CA Q75E was evaluated. The expression of pKAT/total AKT was compared across canonical PIK3CA E545K mutation, non-canonical… (full text at CIViC) PMID 34779417 · Jin et al., 2021 · Open in CIViC	civic
PIK3CA Q75E	Alpelisib	Predictive	C	Supports Sensitivity Response	2	submitted	EID12159 A 55-year-old man with HNSCC harbouring PIK3CA Q75E (non-canonical) mutation was previously treated and responded to concurrent chemoradiation therapy (CRT) with cisplatin, however, experienced local … (full text at CIViC) PMID 34779417 · Jin et al., 2021 · Open in CIViC

ClinVar

Clinical significance (0)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

Data not yet available

No ClinVar interpretation attached to this variant.